Neurizon Therapeutics Overview
- Year Founded
-
2000

- Status
-
Public
- Employees
-
52

- Stock Symbol
-
NUZ

- Investments
-
2
- Share Price
-
$0.11
- (As of Thursday Closing)
Neurizon Therapeutics General Information
Description
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).
Contact Information
Website
www.neurizon.comCorporate Office
- Level 4
- 96-100 Albert Road
- South Melbourne, Victoria 3205
- Australia
Corporate Office
- Level 4
- 96-100 Albert Road
- South Melbourne, Victoria 3205
- Australia
Neurizon Therapeutics Timeline
Neurizon Therapeutics Stock Performance
As of 19-Jun-2025, Neurizon Therapeutics’s stock price is $0.11. Its current market cap is $54.5M with 492M shares.
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.11 | $0.10 | $0.06 - $0.16 | $54.5M | 492M | 328K |
Neurizon Therapeutics Financials Summary
As of 31-Mar-2025, Neurizon Therapeutics has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
---|---|---|---|---|
EV | 31,409 | 53,848 | 16,154 | 14,552 |
Revenue | 1,898 | 2,450 | ||
EBITDA | (5,847) | (3,956) | (946) | |
Net Income | (5,029) | (4,176) | (1,238) | |
Total Assets | 7,436 | 4,058 | 6,933 | |
Total Debt | 0 | 694 | 953 |
Neurizon Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Neurizon Therapeutics Comparisons
Industry
Financing
Details
Neurizon Therapeutics Competitors (7)
One of Neurizon Therapeutics’s 7 competitors is Novartis, a Corporation company based in Basel, Switzerland.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Novartis | Corporation | Basel, Switzerland | ||||
Zynerba Pharmaceuticals | Formerly VC-backed | Plymouth, PA | ||||
Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
Genelux | Formerly VC-backed | Westlake Village, CA | ||||
Dynavax Technologies | Formerly VC-backed | Emeryville, CA |
Neurizon Therapeutics Signals
Neurizon Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Neurizon Therapeutics Acquisitions (2)
Neurizon Therapeutics’s most recent deal was a Merger/Acquisition with Pitney Pharmaceuticals for . The deal was made on 13-Aug-2013.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Pitney Pharmaceuticals | 13-Aug-2013 | Merger/Acquisition | Other Healthcare Technology Systems | ||
Pela Resources | 10-Sep-2012 | Merger/Acquisition | Precious Metals and Minerals Mining |
Neurizon Therapeutics FAQs
-
When was Neurizon Therapeutics founded?
Neurizon Therapeutics was founded in 2000.
-
Where is Neurizon Therapeutics headquartered?
Neurizon Therapeutics is headquartered in South Melbourne, Australia.
-
What is the size of Neurizon Therapeutics?
Neurizon Therapeutics has 52 total employees.
-
What industry is Neurizon Therapeutics in?
Neurizon Therapeutics’s primary industry is Drug Discovery.
-
Is Neurizon Therapeutics a private or public company?
Neurizon Therapeutics is a Public company.
-
What is Neurizon Therapeutics’s stock symbol?
The ticker symbol for Neurizon Therapeutics is NUZ.
-
What is the current stock price of Neurizon Therapeutics?
As of 19-Jun-2025 the stock price of Neurizon Therapeutics is $0.11.
-
What is the current market cap of Neurizon Therapeutics?
The current market capitalization of Neurizon Therapeutics is $54.5M.
-
Who are Neurizon Therapeutics’s competitors?
Novartis, Zynerba Pharmaceuticals, Inovio Pharmaceuticals, Genelux, and Dynavax Technologies are some of the 7 competitors of Neurizon Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »